An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

This is an open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult
patients with lymphoma or multiple myeloma. The patient population will consist of adults
with a confirmed diagnosis of lymphoma (Waldenstrom's macroglobulinemia is permitted) or
multiple myeloma that is relapsed and/or refractory after at least 2 prior standard
chemotherapeutic regimens and for which no curative option exists.

Patients in the expansion cohort, Schedule E, must specifically have Hodgkin lymphoma,
DLBCL-GCB subtype, DLBCL-non-GCB subtype, or Mantle Cell Lymphoma (MCL). Patients with
multiple myeloma will no longer be evaluated as a part of this study.